*Corresponding author:
Ngai Siew Ching, School of Biosciences, Faculty of Science, University of Nottingham Malaysia Campus, 43500 Semenyih, Selangor, MalaysiaReceived: April 09, 2018; Published: April 20, 2018
DOI: 10.26717/BJSTR.2018.04.000987
To view the Full Article Peer-reviewed Article PDF
Tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a promising anti-cancer agent due to its selective killing of cancer cells, sparing the vital normal cells. Despite its great potential in cancer treatment, its clinical application has been hampered by the cancer resistance. Various strategies have been developed to overcome resistance towards TRAIL-induced apoptosis which include the combinational therapy of TRAIL with epigenetic drugs, chemotherapy drugs and the autophagy inhibitors. To heighten the therapeutic outcome, the personalized medicine based on biomarker screening could serve as a novel strategy in tailoring the combinational therapy of TRAIL and sensitizer for targeted cancer therapy in the near future.
Abbrevation: TNF: Tumour Necrosis Factor; TRAIL: Tumour Necrosis Factor Related Apoptosis-Inducing Ligand; DISC: Death Inducing Signalling Complex; FADD: Fas Associated Death Domain
Abstract| Introduction| Resistance| Sensitization of Cancer Cells Towards TRAIL-Induced Apoptosis| Conclusion and Future Prospects| References|